Talphera Inc

NASDAQ:TLPHUnited States

Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.

Contact Information

Headquarters

1850 Gateway Drive, Suite 175SAN MATEO, CA, United States 94404

Phone

650-216-3500

Fax

302-636-5454

Executives

Independent Chairman of the Board

Adrian Adams

Chief Executive Officer, Director

Vincent Angotti

Chief Financial Officer

Raffi Asadorian

Chief Development Officer, Chief Medical Officer

Shakil Aslam

Chief Engineering Officer

Badri Dasu